Chelators and metal complex stability for radiopharmaceutical applications

被引：44

作者：

Okoye, Nkemakonam C. ^{[1
]}

Baumeister, Jakob E. ^{[1
]}

Khosroshahi, Firouzeh Najafi ^{[1
]}

Hennkens, Heather M. ^{[1
,2
]}

Jurisson, Silvia S. ^{[1
]}

机构：

[1] Univ Missouri, Dept Chem, Columbia, MO 65211 USA

[2] Univ Missouri, Res Reactor Ctr, Columbia, MO 65211 USA

来源：

RADIOCHIMICA ACTA | 2019年 / 107卷 / 9-11期

关键词：

Radiopharmaceutical; radiometal; bifunctional chelate; diagnostic imaging; radionuclide therapy; chelator; MIXED-LIGAND COMPLEXES; IN-VIVO EVALUATION; TECHNETIUM TRICARBONYL COMPLEXES; SMALL-MOLECULE INHIBITORS; POTENTIAL IMAGING PROBES; BIOLOGICAL EVALUATION; SCHIFF-BASE; BIFUNCTIONAL CHELATOR; MONOCLONAL-ANTIBODIES; PRECLINICAL EVALUATION;

D O I：

10.1515/ract-2018-3090

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

Diagnostic and therapeutic nuclear medicine relies heavily on radiometal nuclides. The most widely used and well-known radionuclide is technetium-99m (Tc-99m), which has dominated diagnostic nuclear medicine since the advent of the Mo-99/Tc-99m generator in the 1960s. Since that time, many more radiometals have been developed and incorporated into potential radiopharmaceuticals. One critical aspect of radiometal-containing radiopharmaceuticals is their stability under in vivo conditions. The chelator that is coordinated to the radiometal is a key factor in determining radiometal complex stability. The chelators that have shown the most promise and are under investigation in the development of diagnostic and therapeutic radiopharmaceuticals over the last 5 years are discussed in this review.

引用

页码：1087 / 1120

页数：34

共 211 条

[1] A novel organometallic aqua complex of technetium for the labeling of biomolecules:: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand [J].